profit from every $100 of sales.
$0$100
Ekso Bionics Holdings
We have no price for Ekso Bionics Holdings since 15 May 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$11.80+1.29% today
+125.2% since Oct 8, 25
1-year low $3.871-year high $12.95
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Ekso Bionics Holdings sold, what it kept, and what it did with the cash.
Sales went from $12.9 million in 2022 to $12.8 million in 2025, with -$11.7 million of profit last year.
SalesProfit
Ekso Bionics Holdings vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Ekso Bionics Holdings | No profit yet | ||
 Concentra Group Holdings Parent | 33.0× · Expensive | ||
 Hims & Hers Health | 38.0× · Expensive | ||
 Envista | 86.4× · Very expensive | ||
 Beta Bionics | No profit yet |
AI analysis
An AI analyst reads Ekso Bionics Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 13 | 18 | 18 | 13 | |
| 6 | 9 | 10 | 7 | |
| -16 | -15 | -10 | -13 | |
| -14 | -13 | -9 | -10 | |
| -15 | -15 | -11 | -12 | |
| -17.40 | -16.50 | -8.40 | -4.91 | |
| 48.1% | 49.7% | 53.1% | 53.5% | |
| -120.5% | -82.7% | -58.4% | -104.1% | |
| -116.8% | -83.1% | -63.2% | -91.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 41 | 29 | 27 | 20 |
| Cash | 21 | 9 | 4 | 1 |
| Total debt | 8 | 7 | 6 | 5 |
| Total liabilities | 15 | 16 | 14 | 11 |
| 25 | 13 | 13 | 9 | |
| 1 | 1 | 1 | 2 | |
| -35.8% | -59.5% | -46.8% | -65.8% | |
| -59.3% | -120.6% | -89.2% | -129.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -15 | -12 | -10 | -12 | |
| 0 | 0 | 0 | 0 | |
| -15 | -12 | -10 | -12 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 3 | 2 | 2 | 2 |
Valuation
- –
- –
- –
- –
- 2.2×
- –
- –
- -41.9%
- -40.9%
- –
Profitability
- 53.5%
- -104.1%
- -91.4%
- –
- –
- –
- –
- –
- –
- –
Growth
- −0.3%
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 888
Bottom 17%of 889
Bottom 1%of 987
What analysts expect
- Average price target
- $6.00
- Range
- $6.00 – $6.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 28, 2026 | -2.04 | -0.03 | −6,700.0% |
| Feb 23, 2026 | -1.56 | -0.08 | −1,850.0% |
| Oct 28, 2025 | -0.54 | -0.99 | +45.5% |
| Jul 28, 2025 | -1.24 | -1.20 | −3.3% |
| May 5, 2025 | -1.80 | -1.65 | −9.1% |
| Mar 3, 2025 | -0.14 | -0.07 | −100.0% |
| Oct 28, 2024 | -0.10 | -0.08 | −25.0% |
| Jul 29, 2024 | -0.13 | -0.11 | −18.2% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
23No pass
Benjamin Graham
47No pass
Philip Fisher
36No pass
Peter Lynch
13No pass
Joel Greenblatt
0No pass
Charlie Munger
35No pass
Terry Smith
33No pass
Questions about Ekso Bionics Holdings
Is Ekso Bionics Holdings a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Ekso Bionics Holdings AI analysis
What does Ekso Bionics Holdings do?
Ekso Bionics Holdings, Inc. designs, develops, distributes, and commercializes exoskeleton products in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It is in Medical - Equipment & Services.
Does Ekso Bionics Holdings pay a dividend?
No. Ekso Bionics Holdings does not pay a dividend at the moment.
Who are Ekso Bionics Holdings's competitors?
The largest listed companies in the same industry are Concentra Group Holdings Parent, Hims & Hers Health, Envista and Beta Bionics. The peers table on this page compares their profit, growth and price with Ekso Bionics Holdings's.
Prices: daily closes to May 15, 2026. Fundamentals: company reports via invest-like data.